CIK 0001933414 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Mineralys Therapeutics, Inc.
Sign in to watch- Ticker
- MLYS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 841966887
- Phone
- (888) 378-6240
- Business address
- 150 N. RADNOR CHESTER ROAD, SUITE F200, RADNOR, PA
- 4 Grant or award Director acquired 6,200 shares (grant or award)
- 4 Grant or award Director acquired 6,200 shares (grant or award)
- 4 Grant or award Director acquired 6,200 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 38,400 shares (grant or award)
- 4 Grant or award CFO and Secretary acquired 39,900 shares (grant or award)
- 4 Planned sale Chief Medical Officer sold 417 shares at $27.59 ($11,505)
- 4 Planned sale Chief Medical Officer sold 20,404 shares at an average $27.93 ($569,809)
- 4 Planned sale Chief Medical Officer sold 2,171 shares at $30.21 ($65,586)
- 4 Planned sale Chief Medical Officer sold 416 shares at $32.10 ($13,354)
- 4 Planned sale Chief Medical Officer sold 19,076 shares at an average $32.66 ($623,115)
- 4 Planned sale Chief Executive Officer sold 16,236 shares at an average $32.62 ($529,640)
- 4 Planned sale CFO and Secretary sold 10,758 shares at $32.14 ($345,723)
- 4 Planned sale Chief Medical Officer sold 8,518 shares at an average $32.56 ($277,339)
- 4 Planned sale Chief Medical Officer sold 262,752 shares at an average $35.25 ($9,261,028)
- 4 Option exercise Chief Executive Officer acquired 24,082 shares (option exercise)
- 4 Open-market sale Director sold 1,000,000 shares at $43.35 ($43,350,000)
- 4 Open-market sale CFO and Secretary sold 119,524 shares at an average $44.88 ($5,363,716)
- 4 Open-market sale Chief Executive Officer sold 200,000 shares at an average $45.44 ($9,088,499)
- 4 Open-market sale Director sold 15,000 shares at an average $45.99 ($689,797)
- 4 Open-market sale Director sold 34,675 shares at an average $45.45 ($1,576,095)
Page 3 of 9 · 180 filings